Introduction
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies in men, and its incidence and mortality continue to be a significant clinical problem. Recent evidence from our lab identified MEIS1, an important HOX protein cofactor, as a potential tumor suppressor. Patients bearing MEIS1-positive prostate tumors were less likely to have biochemical recurrence and metastasis compared to men bearing MEIS-negative tumors. Androgen receptor (AR), the major oncogene in PCa, has been shown to interact with HOXB13 to promote prostate cancer progression, but the function of MEIS proteins to antagonize AR/HOXB13 interactions are unknown. We hypothesize that MEIS1 proteins interact with HOXB13 to suppress cancer initiation and progression, and loss of MEIS1 expression in a portion of prostate tumors enables oncogenic AR/HOXB13 interactions.

Results
We found that AR expression was significantly increased when MEIS1 was ectopically expressed compared to controls and HOXB13 knock-out lines. Re-expression of MEIS1 enhanced the binding between HOXB13-MEIS and AR-MEIS, and reduced the AR-HOXB13 interaction. In castrated mice, re-expression of MEIS1 significantly decreased the tumor formation and tumor growth rate compared to hormonally intact nude mice. Conversely, xenografts of HOXB13-knockout tumors showed an increased rate of tumor growth and tumor formation compared to MEIS1-expressing cells and controls in both hormonally intact and castrated nude mice.

Re-expression of MEIS1 increases AR expression in PCa cells

![Western Blot Analysis of AR Expression](image1)

Figure 1: (A, C) Western blot analysis of AR expression in Cas9 controls, re-expression of MEIS1, HOXB13KO and HOXB13KO-MEIS lines derived from LAPC4 and CWR22Rv1. Cell lines were tested for AR sensitivity with AR agonist (R1881) or antagonist (Enzalutamide). (B, D) Quantification of AR gene expression. Data represent mean ± SD and comparisons among groups were evaluated with one-way ANOVA. *p < 0.05

Increased MEIS1 expression enhances the binding between HOXB13-MEIS and reduces the oncogenic AR-HOXB13 interaction

![Imaging](image2)

Figure 2: PLA was performed and quantified for the interactions between HOXB13-AR and HOXB13-MEIS in Cas9-GFP controls and MEIS1 lines of CWR22Rv1 (A, B) and LAPC4 (C, D). PLA signals were imaged as Texas Red, and pseudo colored yellow for increased contrast with nuclei marked by DAPI. The number of PLA signals per nucleus were counted using ImageJ. *p < 0.05

Re-expression of MEIS1 suppresses tumor formation and increases the in vivo sensitivity to host castration

![Survival Curves](image3)

Figure 4: Kaplan-Meier survival curves illustrating increased overall survival rate of castrate- and hormonally intact- nude mice when xenografted with MEIS1, followed by HOXB13KO-MEIS compared to Cas9 controls and HOXB13KO lines derived from LAPC4 (A, B) and CWR22Rv1 cells (C, D) to reach 1.5 cc tumor volume.

Conclusions
Our collective data supports our hypothesis that increased MEIS1 expression reduces the AR/HOXB13 interaction and increases the in vivo sensitivity to host castration; this suggests that MEIS-positive cells have decreased oncogenic AR signaling. Future RNAseq studies will determine the global impact of MEIS expression on AR gene targeting in PCa and provide us a strong rationale to support the potential utility of MEIS proteins as predictive clinical biomarkers of metastatic progression.

Acknowledgements
This work was supported by the Urology Care Foundation and Chesapeake Urology Associates. DOD grant PC130587, and DOD grant PC180414

Contact: sperike@uic.edu